Austin Rynders's Profile

Role	Title	Level	Year	L/R
🐜	Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression 8 auth. S. Vucic, M. Kiernan, P. Menon, W. Huynh, Austin Rynders, Karen S. Ho, ... R. Glanzman, M. Hotchkin	5	2021	5 🐜
🐜	Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension 13 auth. S. Vucic, P. Menon, W. Huynh, Colin J Mahoney, Karen S. Ho, A. Hartford, Austin Rynders, Jacob Evan, Jeremy Evan, Shelia Ligozio, ... R. Glanzman, M. Hotchkin, M. Kiernan	4	2023	4 🐜
🐜	Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials 11 auth. Jimin Ren, Richard B. Dewey, Austin Rynders, Jacob Evan, Jeremy Evan, Shelia Ligozio, ... Karen S. Ho, Peter V. Sguigna, R. Glanzman, M. Hotchkin, Benjamin M. Greenberg	3	2023	3 🐜
🐬	Ventilatory Response to Hypercapnia as Experimental Model to Study Effects of Oxycodone on Respiratory Depression. L. Webster, Erik Hansen, G. Stoddard, Austin Rynders, D. Ostler, Harley Lennon	2	2021	2 🐬
🐜	CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial. 90 auth. James D. Berry, N. Maragakis, Eric A Macklin, Lori B. Chibnik, Melanie Quintana, Benjamin R. Saville, M. Detry, Matteo Vestrucci, Joe Marion, A. McGlothlin, Elijah W. Stommel, Marianne K. Chase, Lindsay Pothier, Brittney A. Harkey, Hong Yu, ... Alexander V. Sherman, Jeremy M Shefner, Meghan Hall, Gale Kittle, Suma Babu, Jinsy Andrews, Derek D’Agostino, Eric Tustison, Erica Scirocco, Elisa Giacomelli, Gustavo Alameda, Eduardo Locatelli, Doreen T Ho, Adam Quick, S. Ajroud-Driss, Jonathan Katz, D. Heitzman, Stanley H. Appel, S. Shroff, Kevin J. Felice, Z. Simmons, Timothy M. Miller, Nicholas Olney, Michael D Weiss, Stephen A. Goutman, J. A. Fernandes, O. Jawdat, M. Owegi, Laura Foster, Tuan Vu, H. Ilieva, Daniel S. Newman, Ximena Arcila-Londono, Carlayne E. Jackson, S. Ladha, T. Heiman-Patterson, J. Caress, Andrea Swenson, Amanda Peltier, Richard Lewis, Dominic Fee, Matthew Elliott, Richard S Bedlack, E. Kasarskis, Lauren Elman, Jeffrey Rosenfeld, David Walk, Courtney E. Mcilduff, Paul Twydell, Eufrosina Young, Kristin Johnson, K. Rezania, Namita A Goyal, Jeffrey A. Cohen, Michael Benatar, Vovanti Jones, Jonathan D. Glass, Jaimin Shah, S. Beydoun, J. Wymer, Lindsay Zilliox, Shakti Nayar, Gary L. Pattee, Jennifer M. Martinez-Thompson, Austin Rynders, Jacob Evan, Jeremy Evan, Alan Hartford, Marjan Sepassi, Karen S. Ho, R. Glanzman, Benjamin Greenberg, M. Hotchkin, Sabrina Paganoni, M. Cudkowicz	1	2025	1 🐜
🐜	VISIONARY-MS Top-line Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis (PL5.005) 13 auth. Michael Barnett, H. Beadnall, A. Klistorner, R. Sergott, Benjamin Greenberg, Austin Rynders, Karen Ho, Jacob Evan, Jeremy Evan, Ryan McBride, ... A. Hartford, R. Glanzman, M. Hotchkin	0	2023	0 🐜